Efficacy News and Research

RSS
Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

Medical Imaging Holdings acquires Sonora Medical Systems business from Misonix

Medical Imaging Holdings acquires Sonora Medical Systems business from Misonix

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

Inviragen, SingVax merge their complementary vaccine pipelines

Inviragen, SingVax merge their complementary vaccine pipelines

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

Pico-Tesla commences Phase III clinical trial its Resonator system for treating Parkinson’s disease

Pico-Tesla commences Phase III clinical trial its Resonator system for treating Parkinson’s disease

Antibiotic minocycline may be used for treatment of strokes: Study

Antibiotic minocycline may be used for treatment of strokes: Study

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Preclinical study results of AVL-181 protease inhibitor presented

Preclinical study results of AVL-181 protease inhibitor presented

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.